Business
Future Farm Strengthens Its Foothold in the Hemp-based CBD Market -- CFN Media
Future Farm Strengthens Its Foothold in the Hemp-based CBD Market -- CFN Media.
About this update from Future Farm Technologies Inc
[{"type":"text","content":"\n\n SEATTLE, WA , Dec. 22, 2017 (GLOBE NEWSWIRE) -- \n CFN Media Group (\"CannabisFN\"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing Future Farm Technologies Inc. (CSE: FFT) (CNSX: FFT) (FFT.CN) (OTCQB: FFRMF), and its place in the expanding market for cannabinoids, the active ingredients in the cannabis plant. Cannabinoid Pharmaceuticals The market for cannabinoid-based pharmaceuticals is projected to grow from $2 billion in 2020 to more than $50 billion by 2029, according to Statista, driven by increasing interest among pharmaceutical companies. While GW Pharmaceuticals plc and Insys Therapeutics Inc. may be the most widely known companies in the space, many smaller companies have development-stage programs in the works. Cannabinoid compounds, like cannabidiol (CBD), have demonstrated promise in treating many different underlying medical conditions without the side effects of traditional pharmaceutical drugs. According to Google Scholar, there have been more than 2,000 papers published about CBD this year alone. Many companies have also become increasingly interested in the therapeutic potential for the cannabinoid, as evidenced by the more than 1,600 U.S. patents that have been issued mentioning CBD. For example, GW Pharmaceuticals’ Sativex® has been shown to be effective in treating central and peripheral neuropathic pain, rheumatoid arthritis, and cancer pain in numerous randomized clinical trials and has far fewer side effects than addictive opioids. The traditional pharmaceutical industry has largely steered clear of the cannabinoid-based industry due to the legal status of cannabis in the United States. With many of these companies facing so-called patent cliffs over the coming years, and cannabis legalization taking hold across the U.S., smaller companies with promising clinical programs could see interest on the part of larger pharmaceutical companies looking to expand their portfolios. Cannabinoids are being studied for treatment of many multi-billion dollar conditions including psoriasis/skin conditions, epilepsy, Parkinson's disease, inflammation, and pain. Future Farm’s Unique Position Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) is laying the groundwork to supply the cannabinoids...